Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: A Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial.
Ruchong Chen, Yuanrong Dai, Danrong Yang, Chuntao Liu, Wei Han, Wei Gu, Jie Cao, Qiong Zhou, Peter Howarth, Stephen Weng, Cui Xiong, Jie Huang, Peiwen Liang, Nanshan Zhong, 201536 Study Group
Allergy Asthma Immunol Res 17(4) 473-485
摘要
摘要
PURPOSE: Clinical remission (CR), an emerging treatment goal in asthma, was assessed by a post hoc analysis of a phase 3 study of mepolizumab in severe asthma with an eosinophilic phenotype (SA-EP). METHODS: Asthmatic patients aged ≥ 12 years, with a blood eosinophil count of ≥ 150 cells/µL at screening (or ≥ 300 cells/µL in the previous year), receiving fluticasone propionate ≥ 500 µg/day or equivalent plus ≥ 1 controller medication, and experiencing ≥ 2 exacerbations in the previous year were randomised to receive add-on mepolizumab or placebo every 4 weeks for 52 weeks. CR was assessed using both 3- and 4-component definitions (at 1 year, no maintenance oral corticosteroids, no clinically significant exacerbations, and asthma control questionnaire-5 [ACQ-5] score ≤ 1.5 for both, plus change from baseline in pre-bronchodilator forced expiratory volume in 1 second ≥ 0 mL for 4-component definition). RESULTS: At week 52, 41.6% (62/149) of mepolizumab-treated patients and 21.2% (32/151) of placebo-treated patients met the 4-component definition (odds ratio [OR], 2.65; 95% confidence interval [CI], 1.59-4.41; P < 0.001), with a difference of 20.4% (95% CI, 9.1%-31.2%), and 54.4% (81/149) of mepolizumab-treated patients and 32.5% (49/151) of placebo-treated patients met the 3-component definition (OR, 2.48; 95% CI, 1.55-3.96; P < 0.001), with a difference of 21.9% (95% CI, 10.5%-32.7%). Baseline characteristics potentially associated with CR in the mepolizumab group were lower ACQ-5 score and lower St George's Respiratory Questionnaire scores. CONCLUSIONS: A higher proportion of Chinese SA-EP patients treated with mepolizumab achieved CR compared to those receiving placebo. Certain baseline characteristics are potentially predictive of CR. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03562195.
KM 提取结果
0 个 Figure · 0 个 KM 面板